24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Startup: Confidential
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Entera
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
13:55
JVP partners with global insurance leaders to launch international initiative boosting AI technologies in insurtech and climatetech
17:00
AISAP raises $13 Million in Seed for its AI ultrasound solution
16:00
Sam Altman-backed Apex emerges from stealth with $7M to help secure AI adoption
15:20
Gigi Levy-Weiss: "Creating jobs is no longer enough to fulfill one’s Zionist duty; we must change the country"
More stories
Buzz
Most popular
Daily
Weekly
1
Wiz deal to acquire Lacework collapses
2
Nvidia to acquire AI startup Deci for $300 million
3
Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale
4
Sam Altman-backed Apex emerges from stealth with $7M to help secure AI adoption
5
Permira acquiring control of BioCatch at $1.3 billion valuation
More news
Entera
4 stories about Entera
Drug Developer Entera Bio Down on Nasdaq Following Amgen Deal
12.12.18
|
Lilach Baumer
The deal, announced Tuesday, could see Entera receive up to $270 million in aggregate payments
Entera Bio Gives Nasdaq IPO Another Shot
21.05.18
|
Dror Reich
This is the fourth time since 2014 that the Jerusalem-based biomed company files for an initial public offering on Nasdaq
CTech’s Daily Israeli Tech News Roundup
08.01.18
|
CTech
Israeli investment house to open crypto unit. A closer look at the first company funded by Koch’s new venture capital firm. Intuition Robotics expands funding round, nabbing Samsung as an investor.
For the Fourth Time, Entera Bio Tries for Nasdaq IPO
08.01.18
|
Dror Reich
The Jerusalem-based biomed company plans to raise $55 million, with Oppenheimer & Co. as the sole underwriter
Please ensure Javascript is enabled for purposes of
website accessibility